Mangalam Drugs & Organics (NSE:MANGALAM) Other Operating Expense: ₹1,062 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
38 GF Score
Price ₹27.22
GF Value ₹62.49
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Other Operating Expense?

Mangalam Drugs & Organics NSE:MANGALAM +0.18% 38 Other Operating Expense is ₹1,062 Mil as of Mar. 2026. GuruFocus rates NSE:MANGALAM with a GF Score™ of 38/100 and a GF Value™ of ₹62.49 (Possible Value Trap). The stock has 4 warning signs investors should review.

Mangalam Drugs & Organics's Other Operating Expense for the three months ended in Mar. 2026 was ₹304 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,062 Mil.

Mangalam Drugs & Organics's quarterly Other Operating Expense increased from Sep. 2025 (₹237 Mil) to Dec. 2025 (₹272 Mil) and increased from Dec. 2025 (₹272 Mil) to Mar. 2026 (₹304 Mil).

Mangalam Drugs & Organics's annual Other Operating Expense increased from Mar. 2024 (₹844 Mil) to Mar. 2025 (₹1,137 Mil) but then declined from Mar. 2025 (₹1,137 Mil) to Mar. 2026 (₹1,084 Mil).

Mangalam Drugs & Organics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Other Operating Expense Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 712.63 686.40 843.74 1,136.79 1,083.83

Mangalam Drugs & Organics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 322.20 249.01 236.67 271.95 304.03
NSE:MANGALAM
38GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,062 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of ₹1,062 Mil mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Other Operating Expense of ₹1,062 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Other Operating Expense too high?
Mangalam Drugs & Organics' current Other Operating Expense is ₹1,062 Mil. Overall, Mangalam Drugs & Organics has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Other Operating Expense compare to ZTS?
Mangalam Drugs & Organics' Other Operating Expense of ₹1,062 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Other Operating Expense is ₹1,062 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹62.49, compared to a current price of ₹27.22 — trading 56.4% below its estimated fair value. The current Other Operating Expense is ₹1,062 Mil. Mangalam Drugs & Organics' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Other Operating Expense is ₹1,062 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹27.22 is trading 56.4% below its estimated GF Value™ of ₹62.49. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Other Operating Expense: ₹1,062 Mil
  • GF Value™: ₹62.49 vs. price of ₹27.22 (56.4% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
38GF Score

Get the complete analysis for NSE:MANGALAM

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹27.22
Price
₹62.49
GF Value